TY - JOUR AU - Jackman, D. AU - Pao, W. AU - Riely, G. J. AU - Engelman, J. A. AU - Kris, M. G. AU - Janne, P. A. PY - 2010 DA - 2010// TI - Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.24.7049 DO - 10.1200/JCO.2009.24.7049 ID - Jackman2010 ER - TY - JOUR AU - Codd, A. S. AU - Kanaseki, T. AU - Torigo, T. AU - Tabi, Z. PY - 2018 DA - 2018// TI - Cancer stem cells as targets for immunotherapy JO - Immunology. VL - 153 UR - https://doi.org/10.1111/imm.12866 DO - 10.1111/imm.12866 ID - Codd2018 ER - TY - JOUR AU - MacDonagh, L. AU - Gray, S. G. AU - Breen, E. AU - Cuffe, S. AU - Finn, S. P. AU - O'Byrne, K. J. PY - 2016 DA - 2016// TI - Lung cancer stem cells: the root of resistance JO - Cancer Lett VL - 372 UR - https://doi.org/10.1016/j.canlet.2016.01.012 DO - 10.1016/j.canlet.2016.01.012 ID - MacDonagh2016 ER - TY - JOUR AU - Batlle, E. AU - Clevers, H. PY - 2017 DA - 2017// TI - Cancer stem cells revisited JO - Nat Med VL - 23 UR - https://doi.org/10.1038/nm.4409 DO - 10.1038/nm.4409 ID - Batlle2017 ER - TY - JOUR AU - Kharkar, P. S. PY - 2017 DA - 2017// TI - Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015) JO - Expert Opin Ther Pat VL - 27 UR - https://doi.org/10.1080/13543776.2017.1325465 DO - 10.1080/13543776.2017.1325465 ID - Kharkar2017 ER - TY - JOUR AU - Chiu, C. F. AU - Chang, Y. W. AU - Kuo, K. T. AU - Shen, Y. S. AU - Liu, C. Y. AU - Yu, Y. H. PY - 2016 DA - 2016// TI - NF-kappaB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance JO - Proc Natl Acad Sci U S A VL - 113 UR - https://doi.org/10.1073/pnas.1522612113 DO - 10.1073/pnas.1522612113 ID - Chiu2016 ER - TY - JOUR AU - Yamamoto, A. AU - Nagano, T. AU - Takehara, S. AU - Hibi, M. AU - Aizawa, S. PY - 2005 DA - 2005// TI - Shisa promotes head formation through the inhibition of receptor protein maturation for the caudalizing factors, Wnt and FGF JO - Cell VL - 120 UR - https://doi.org/10.1016/j.cell.2004.11.051 DO - 10.1016/j.cell.2004.11.051 ID - Yamamoto2005 ER - TY - JOUR AU - Wang, K. a. i. x. u. a. n. AU - Ji, W. e. n. x. i. a. n. g. AU - Yu, Y. o. n. g. f. e. n. g. AU - Li, Z. i. m. i. n. g. AU - Niu, X. i. a. o. m. i. n. AU - Xia, W. e. i. l. i. a. n. g. AU - Lu, S. h. u. n. PY - 2018 DA - 2018// TI - FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer JO - Oncogene VL - 37 UR - https://doi.org/10.1038/s41388-018-0311-3 DO - 10.1038/s41388-018-0311-3 ID - Wang2018 ER - TY - JOUR AU - Lu, T. AU - Li, Z. AU - Yang, Y. AU - Ji, W. AU - Yu, Y. AU - Niu, X. PY - 2018 DA - 2018// TI - The hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer JO - Cancer Lett VL - 423 UR - https://doi.org/10.1016/j.canlet.2018.02.015 DO - 10.1016/j.canlet.2018.02.015 ID - Lu2018 ER - TY - JOUR AU - Chen, C. C. AU - Chen, H. Y. AU - Su, K. Y. AU - Hong, Q. S. AU - Yan, B. S. AU - Chen, C. H. PY - 2014 DA - 2014// TI - Shisa3 is associated with prolonged survival through promoting beta-catenin degradation in lung cancer JO - Am J Respir Crit Care Med VL - 190 UR - https://doi.org/10.1164/rccm.201312-2256OC DO - 10.1164/rccm.201312-2256OC ID - Chen2014 ER - TY - JOUR AU - Pao, W. AU - Miller, V. A. AU - Politi, K. A. AU - Riely, G. J. AU - Somwar, R. AU - Zakowski, M. F. PY - 2005 DA - 2005// TI - Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain JO - PLoS Med VL - 2 UR - https://doi.org/10.1371/journal.pmed.0020073 DO - 10.1371/journal.pmed.0020073 ID - Pao2005 ER - TY - JOUR AU - Thress, K. S. AU - Paweletz, C. P. AU - Felip, E. AU - Cho, B. C. AU - Stetson, D. AU - Dougherty, B. PY - 2015 DA - 2015// TI - Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M JO - Nat Med VL - 21 UR - https://doi.org/10.1038/nm.3854 DO - 10.1038/nm.3854 ID - Thress2015 ER - TY - JOUR AU - Liu, Q. AU - Yu, S. AU - Zhao, W. AU - Qin, S. AU - Chu, Q. AU - Wu, K. PY - 2018 DA - 2018// TI - EGFR-TKIs resistance via EGFR-independent signaling pathways JO - Mol Cancer VL - 17 UR - https://doi.org/10.1186/s12943-018-0793-1 DO - 10.1186/s12943-018-0793-1 ID - Liu2018 ER - TY - JOUR AU - Jacobsen, K. AU - Bertran-Alamillo, J. AU - Molina, M. A. AU - Teixido, C. AU - Karachaliou, N. AU - Pedersen, M. H. PY - 2017 DA - 2017// TI - Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer JO - Nat Commun VL - 8 UR - https://doi.org/10.1038/s41467-017-00450-6 DO - 10.1038/s41467-017-00450-6 ID - Jacobsen2017 ER - TY - JOUR AU - Yu, H. A. AU - Suzawa, K. AU - Jordan, E. AU - Zehir, A. AU - Ni, A. AU - Kim, R. PY - 2018 DA - 2018// TI - Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-2961 DO - 10.1158/1078-0432.CCR-17-2961 ID - Yu2018 ER - TY - JOUR AU - Chang, T. H. AU - Tsai, M. F. AU - Su, K. Y. AU - Wu, S. G. AU - Huang, C. P. AU - Yu, S. L. PY - 2011 DA - 2011// TI - Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor JO - Am J Respir Crit Care Med VL - 183 UR - https://doi.org/10.1164/rccm.201009-1440OC DO - 10.1164/rccm.201009-1440OC ID - Chang2011 ER - TY - JOUR AU - Furugaki, K. AU - Fukumura, J. AU - Iwai, T. AU - Yorozu, K. AU - Kurasawa, M. AU - Yanagisawa, M. PY - 2016 DA - 2016// TI - Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification JO - Int J Cancer VL - 138 UR - https://doi.org/10.1002/ijc.29848 DO - 10.1002/ijc.29848 ID - Furugaki2016 ER - TY - JOUR AU - Piotrowska, Z. AU - Isozaki, H. AU - Lennerz, J. K. AU - Gainor, J. F. AU - Lennes, I. T. AU - Zhu, V. W. PY - 2018 DA - 2018// TI - Landscape of acquired resistance to Osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with Osimertinib and BLU-667 for acquired RET fusion JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-1022 DO - 10.1158/2159-8290.CD-18-1022 ID - Piotrowska2018 ER - TY - JOUR AU - Shien, K. AU - Toyooka, S. AU - Yamamoto, H. AU - Soh, J. AU - Jida, M. AU - Thu, K. L. PY - 2013 DA - 2013// TI - Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-4136 DO - 10.1158/0008-5472.CAN-12-4136 ID - Shien2013 ER - TY - JOUR AU - Yu, F. AU - Liu, J. B. AU - Wu, Z. J. AU - Xie, W. T. AU - Zhong, X. J. AU - Hou, L. K. PY - 2018 DA - 2018// TI - Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14 JO - Cancer Lett VL - 427 UR - https://doi.org/10.1016/j.canlet.2018.04.022 DO - 10.1016/j.canlet.2018.04.022 ID - Yu2018 ER - TY - JOUR AU - Wu, S. G. AU - Shih, J. Y. PY - 2018 DA - 2018// TI - Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer JO - Mol Cancer VL - 17 UR - https://doi.org/10.1186/s12943-018-0777-1 DO - 10.1186/s12943-018-0777-1 ID - Wu2018 ER - TY - JOUR AU - Datta, J. AU - Damodaran, S. AU - Parks, H. AU - Ocrainiciuc, C. AU - Miya, J. AU - Yu, L. PY - 2017 DA - 2017// TI - Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398 JO - Mol Cancer Ther VL - 16 UR - https://doi.org/10.1158/1535-7163.MCT-15-1010 DO - 10.1158/1535-7163.MCT-15-1010 ID - Datta2017 ER - TY - JOUR AU - Re, M. AU - Arrigoni, E. AU - Restante, G. AU - Passaro, A. AU - Rofi, E. AU - Crucitta, S. PY - 2018 DA - 2018// TI - Concise review: resistance to tyrosine kinase inhibitors in non-small cell lung Cancer: the role of Cancer stem cells JO - Stem Cells VL - 36 UR - https://doi.org/10.1002/stem.2787 DO - 10.1002/stem.2787 ID - Re2018 ER - TY - JOUR AU - Takahashi-Yanaga, F. AU - Kahn, M. PY - 2010 DA - 2010// TI - Targeting Wnt signaling: can we safely eradicate cancer stem cells? JO - Clin Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-09-2943 DO - 10.1158/1078-0432.CCR-09-2943 ID - Takahashi-Yanaga2010 ER - TY - JOUR AU - Takebe, N. AU - Harris, P. J. AU - Warren, R. Q. AU - Ivy, S. P. PY - 2011 DA - 2011// TI - Targeting cancer stem cells by inhibiting Wnt, notch, and hedgehog pathways JO - Nat Rev Clin Oncol VL - 8 UR - https://doi.org/10.1038/nrclinonc.2010.196 DO - 10.1038/nrclinonc.2010.196 ID - Takebe2011 ER - TY - JOUR AU - Maehara, O. AU - Suda, G. AU - Natsuizaka, M. AU - Ohnishi, S. AU - Komatsu, Y. AU - Sato, F. PY - 2017 DA - 2017// TI - Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma JO - Carcinogenesis. VL - 38 UR - https://doi.org/10.1093/carcin/bgx095 DO - 10.1093/carcin/bgx095 ID - Maehara2017 ER - TY - JOUR AU - Zhou, J. AU - Wulfkuhle, J. AU - Zhang, H. AU - Gu, P. AU - Yang, Y. AU - Deng, J. PY - 2007 DA - 2007// TI - Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance JO - Proc Natl Acad Sci U S A VL - 104 UR - https://doi.org/10.1073/pnas.0702596104 DO - 10.1073/pnas.0702596104 ID - Zhou2007 ER - TY - JOUR AU - Lai, Y. AU - Yu, X. AU - Lin, X. AU - He, S. PY - 2016 DA - 2016// TI - Inhibition of mTOR sensitizes breast cancer stem cells to radiation-induced repression of self-renewal through the regulation of MnSOD and Akt JO - Int J Mol Med VL - 37 UR - https://doi.org/10.3892/ijmm.2015.2441 DO - 10.3892/ijmm.2015.2441 ID - Lai2016 ER - TY - JOUR AU - Qian, X. AU - Anzovino, A. AU - Kim, S. AU - Suyama, K. AU - Yao, J. AU - Hulit, J. PY - 2014 DA - 2014// TI - N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties JO - Oncogene. VL - 33 UR - https://doi.org/10.1038/onc.2013.310 DO - 10.1038/onc.2013.310 ID - Qian2014 ER - TY - JOUR AU - Li, R. AU - Ding, C. AU - Zhang, J. AU - Xie, M. AU - Park, D. AU - Ding, Y. PY - 2017 DA - 2017// TI - Modulation of Bax and mTOR for Cancer therapeutics JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-16-2356 DO - 10.1158/0008-5472.CAN-16-2356 ID - Li2017 ER - TY - JOUR AU - Chen, B. W. AU - Chen, W. AU - Liang, H. AU - Liu, H. AU - Liang, C. AU - Zhi, X. PY - 2015 DA - 2015// TI - Inhibition of mTORC2 induces cell-cycle arrest and enhances the cytotoxicity of doxorubicin by suppressing MDR1 expression in HCC cells JO - Mol Cancer Ther VL - 14 UR - https://doi.org/10.1158/1535-7163.MCT-15-0029 DO - 10.1158/1535-7163.MCT-15-0029 ID - Chen2015 ER - TY - JOUR AU - Zhou, J. AU - Wu, Z. AU - Wong, G. AU - Pectasides, E. AU - Nagaraja, A. AU - Stachler, M. PY - 2017 DA - 2017// TI - CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma JO - Nat Commun VL - 8 UR - https://doi.org/10.1038/ncomms13897 DO - 10.1038/ncomms13897 ID - Zhou2017 ER -